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Abstract
Background: The Human Immunodeficiency virus type 1 (HIV-1) Vpu protein enhances virus
release from infected cells and induces proteasomal degradation of CD4. Recent work identified
BST-2/CD317 as a host factor that inhibits HIV-1 virus release in a Vpu sensitive manner. A current
working model proposes that BST-2 inhibits virus release by tethering viral particles to the cell
surface thereby triggering their subsequent endocytosis.
Results: Here we defined structural properties of BST-2 required for inhibition of virus release
and for sensitivity to Vpu. We found that BST-2 is modified by N-linked glycosylation at two sites
in the extracellular domain. However, N-linked glycosylation was not important for inhibition of
HIV-1 virus release nor did it affect surface expression or sensitivity to Vpu. Rodent BST-2 was
previously found to form cysteine-linked dimers. Analysis of single, double, or triple cysteine
mutants revealed that any one of three cysteine residues present in the BST-2 extracellular domain
was sufficient for BST-2 dimerization, for inhibition of virus release, and sensitivity to Vpu. In
contrast, BST-2 lacking all three cysteines in its ectodomain was unable to inhibit release of wild
type or Vpu-deficient HIV-1 virions. This defect was not caused by a gross defect in BST-2
trafficking as the mutant protein was expressed at the cell surface of transfected 293T cells and was
down-modulated by Vpu similar to wild type BST-2.
Conclusion: While BST-2 glycosylation was functionally irrelevant, formation of cysteine-linked
dimers appeared to be important for inhibition of virus release. However lack of dimerization did
not prevent surface expression or Vpu sensitivity of BST-2, suggesting Vpu sensitivity and inhibition
of virus release are separable properties of BST-2.
Background
Vpu is an 81 amino acid type 1 integral membrane protein
[1,2] that has been shown to cause proteasomal degrada-
tion of CD4 [3,4] but also enhances the release of virions
from infected cells [5-7]. These two biological activities of
Vpu are mechanistically distinct and involve different
structural domains in Vpu. In particular, two conserved
phosphoserine residues in the cytoplasmic domain of Vpu
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(S52, S56) are crucial for CD4 degradation but have no or
only a partial effect on virus release [8-11]. On the other
hand, Vpu's transmembrane (TM) domain is critical for
enhancement of particle release but it can be substituted
by other membrane anchors without effect on CD4 degra-
dation [12,13]
Previous data suggested that Vpu regulates the detach-
ment of otherwise complete virions from the cell surface
[5,14]. Subsequently, several mechanisms of Vpu medi-
ated virus release have been proposed. First, a Vpu-associ-
ated ion channel activity was implicated in the regulation
of virus release. Vpu has the ability to assemble into a
monovalent cation-specific ion channel [15-19]. Rand-
omization of Vpu's TM domain did not affect membrane
association but inhibited Vpu's ion channel activity and,
at the same time, impaired its ability to regulate virus
release [12,17]. These observations established a correla-
tion between Vpu ion channel activity and increased virus
release activity. A second alternative model suggested that
Vpu might interfere with the activity of Task-1, a cellular
ion channel, through the formation of hetero-oligomeric
complexes [20]. Overexpression of a dominant-negative
fragment of Task-1 inhibited Task-1 ion channel activity
and increased release of vpu-deficient particles thus creat-
ing a functional correlation between Task-1 ion channel
activity and reduced HIV-1 particle release [20]. It is not
known, however, if expression of Task-1 is tissue specific
and it remains unclear, exactly how either Vpu or Task-1
ion channel activities might regulate detachment of parti-
cles from the cell surface.
A third model invokes the inactivation of a cellular inhib-
itor of virus release. This model is based on the observa-
tion that Vpu-dependent virus release is host cell-
dependent [21]. Indeed, in addition to Task-1, several
other host factors have been identified whose overexpres-
sion was associated with reduced virus release. These
include the Vpu binding protein UBP [22], the recently
identified host factors BST-2 (also referred to as tetherin,
CD317, or HM1.24 [23,24]), and CAML [25]. Among
those, BST-2 is of particular interest since its cell type-spe-
cific expression most closely matches that of Vpu-depend-
ent cell types and silencing of BST-2 expression in HeLa
cells by siRNA or shRNA rendered virus release from these
cells Vpu-independent [23,24].
A functional Vpu-BST-2 interaction was first reported in a
quantitative membrane proteomics study where Vpu
expressed from an adenovirus vector was found to reduce
cellular expression of BST-2 in HeLa cells [26]. Intrigu-
ingly, subsequent reports found that BST-2 expression var-
ied in a cell type dependent manner; BST-2 mRNA was
constitutively expressed in cell types such as HeLa, Jurkat,
or CD4+ T cells but not 293T or HT1080 cells and thus
corresponded to cell types known to depend on Vpu for
efficient virus release [23,24]. Also, BST-2 expression was
induced by interferon treatment in 293T and HT1080
cells [24] consistent with the previous observation that
interferon treatment of various cell lines that did not nor-
mally require Vpu for efficient virus release became Vpu-
dependent [27]. Additionally, ectopic expression of BST-2
in 293T or HT1080 cells rendered these cells Vpu depend-
ent. This strongly suggested that BST-2 was indeed a host
factor whose inhibitory effect on virus release was coun-
teracted by Vpu [23,24].
BST-2 was originally identified as a membrane protein in
terminally differentiated human B cells of patients with
multiple myeloma [28,29] BST-2 is a 30-36 kDa type II
transmembrane protein, consisting of 180 amino acids
[30]. The protein has both an N-terminal transmembrane
domain and a C-terminal glycosyl-phosphatidylinositol
(GPI) anchor (Fig. 1) [31]. BST-2 protein associates with
lipid rafts at the cell surface and on internal membranes,
presumably the TGN [31]. Also, BST-2 forms stable
cysteine-linked dimers [29] and is modified by N-linked
glycosylation [29,31]. However, the precise function of
these BST-2 modifications remains unknown. N-linked
glycosylation was dispensable for inhibition of Lassa and
Marburg virus release, but the significance of BST-2 glyco-
sylation has not been examined in relation to HIV-1 [32].
Recent data suggest that the BST-2 TM domain is critical
for interference by Vpu [33-35]. consistent with previous
observations of the importance of the Vpu TM domain for
the regulation of virus release [12,13,36]. Furthermore,
antagonism of BST-2 was reported to involve intracellular
reduction of BST-2 levels by Vpu [37-40]. and was shown
to encompass a β-TrCP-dependent endo-lysosomal path-
way [38].
Here we analyzed the functional importance of various
structural properties of BST-2. We show that both pre-
dicted N-linked glycosylation sites are utilized in the
human protein. Interestingly, while endogenous BST-2 in
HeLa cells and other cell types contained almost exclu-
sively complex carbohydrate modifications, a large pro-
portion of transiently expressed BST-2 was modified by
high-mannose carbohydrates, a modification common to
endoplasmic reticulum (ER) resident glycoproteins.
Intriguingly, mutation of both glycosylation sites did not
inhibit cell surface expression of BST-2 and neither abol-
ished sensitivity to Vpu nor eliminated BST-2's inhibitory
effect on HIV-1 particle release. Thus, carbohydrate mod-
ification of BST-2 does not appear to have any functional
significance as far as HIV-1 virus release is concerned. In
contrast, the formation of cysteine linked dimers of BST-2
appeared to be functionally important. We confirmed that
BST-2 forms cysteine-linked dimers involving three
cysteine residues in the extracellular domain. Mutation ofRetrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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individual cysteine residues or of any two of the three
cysteine residues in combination failed to affect BST-2
dimerization and had no effect on BST-2's inhibition of
virus release. In contrast, BST-2 mutated in all three
cysteine residues was unable to inhibit HIV-1 virus
release. Interestingly, this mutant was still expressed at the
cell surface and remained sensitive to Vpu. The inability of
the triple cysteine mutant to inhibit virus release was
therefore not due to gross mislocalization or misfolding
of the protein. Our results suggest that the formation of
cysteine-linked dimers is a critical requirement for the
inhibition of virus release by BST-2.
Methods
Plasmids
The full length infectious HIV-1 molecular clone pNL4-3
and the Vpu deletion mutant pNL4-3/Udel have been
described [5,41] For transient expression of Vpu, the
codon-optimized vector pcDNA-Vphu [42] was
employed. Plasmid pcDNA-BST-2 is a vector for the
expression of human BST-2 under the control of the
cytomegalovirus immediate-early promoter. BST-2 was
amplified by RT-PCR from HeLa mRNA using the primers
5' ATAAC TCGAG GTGGA ATTCA TGGCA TCTAC TTCGT
ATGAC TATTGC and 3' AAGCT TGGTA CCTCA CTGCA
GCAGA GCGCT GAGGC CCAGC AGCAC. The resulting
PCR product was cleaved with XhoI and KpnI and cloned
into the XhoI/KpnI sites of pcDNA3.1(-) (Invitrogen
Corp., Carlsbad CA). Mutation of cysteine residues C53,
C63, and C91 in human BST-2, either alone or in combi-
nation, to alanine was accomplished by PCR-based muta-
genesis of pcDNA-BST-2 and resulted in pcDNA-BST-2
C53A, pcDNA-BST-2 C63A, pcDNA-BST-2 C91A, pcDNA-
BST-2 C12 (C53,63A), pcDNA-BST-2 C13 (C53,91A),
pcDNA-BST-2 C23 (C63,91A), and pcDNA-BST-2 C3A
(C53,63,91A). Mutation of two potential N-linked glyco-
sylation sites was similarly accomplished by PCR-based
mutagenesis and resulted in the change of asparagine res-
idues N65 and N92 to glutamine in human BST-2 either
alone or in combination. PCR products were cloned into
pcDNA-BST-2 to obtain pcDNA-BST-2 N1 (N65Q),
pcDNA-BST-2 N2 (N92Q), and pcDNA-BST-2 N1/N2
(N65,92Q). The presence of the desired mutations and
the absence of additional mutations were verified for each
construct by sequence analysis.
Antisera
Anti-BST-2 antiserum was elicited in rabbits by using a
bacterially expressed MS2-BST-2 fusion protein composed
of amino acids 1 to 91 of the MS2 replicase and amino
acids 41 to 162 of BST-2 generating a polyclonal antibody
against the extracellular portion of BST-2. Polyclonal anti-
Vpu serum (rabbit), directed against the hydrophilic C-
terminal cytoplasmic domain of Vpu expressed in
Escherichia coli [43] was used for detection of Vpu. Serum
from an HIV-positive patient was used to detect HIV-1-
specific capsid (CA) and Pr55gag precursor proteins.
Tubulin was identified using a monoclonal antibody to α-
tubulin (Sigma-Aldrich, Inc., St. Louis MO).
Tissue culture and transfections
HeLa and 293T cells were propagated in Dulbecco's mod-
ified Eagles medium (DMEM) containing 10% fetal
bovine serum (FBS). For transfection, cells were grown in
25 cm2 flasks to about 80% confluency. Cells were trans-
fected using LipofectAMINE PLUS™ (Invitrogen Corp,
Carlsbad CA) following the manufacturer's recommenda-
tions. A total of 5 μg of plasmid DNA per 25 cm2 flask was
Schematic of the BST-2 structure Figure 1
Schematic of the BST-2 structure. (A) BST-2 is a type 2 
integral membrane protein. The N-terminus localizes to the 
cytoplasm. The BST-2 ectodomain contains three cysteine 
residues (C53, C63, C91) and two potential sites for N-
linked glycosylation (N65, N92). The C-terminus of BST-2 is 
modified by the addition of a glycosyl-phosphatidylinositol 
(gpi) anchor. (B) Predicted amino acid sequence of human 
BST-2. The predicted transmembrane region is indicated by a 
box. Signals for N-linked glycosylation are marked in blue; 
cysteine residues in the BST-2 extracellular domain are high-
lighted in yellow. The arrow points to the predicted site of 
cleavage for the addition of the gpi anchor [31].
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used. Total amounts of transfected DNA was kept con-
stant in all samples of any given experiment by adding
empty vector DNA as appropriate. Cells were harvested 24
h post transfection.
Immunoblotting
For immunoblot analysis of intracellular proteins, whole
cell lysates were prepared as follows: Cells were washed
once with PBS, suspended in PBS (400 μl/107 cells), and
mixed with an equal volume of sample buffer (4%
sodium dodecyl sulfate, 125 mM Tris-HCl, pH 6.8, 10%
2-mercaptoethanol, 10% glycerol, and 0.002%
bromophenol blue). For analysis of cysteine mutants
under non-reducing conditions, cells were suspended in
PBS and mixed with an equal volume of sample buffer
that did not contain 2-mercaptoethanol. Proteins were
solubilized by boiling for 10 to 15 min at 95°C with occa-
sional vortexing of the samples to shear cellular DNA.
Residual insoluble material was removed by centrifuga-
tion (2 min, 15,000 rpm in an Eppendorf Minifuge). Cell
lysates were subjected to SDS-PAGE; proteins were trans-
ferred to PVDF membranes and reacted with appropriate
antibodies as described in the text. Membranes were then
incubated with horseradish peroxidase-conjugated sec-
ondary antibodies (Amersham Biosciences, Piscataway
NJ) and visualized by enhanced chemiluminescence
(ECL, Amersham Biosciences).
Metabolic labeling and immunoprecipitations
Cells were transfected as described in the text with con-
stant amounts of proviral vectors and increasing amounts
of BST-2. Twenty-four hours later, cells were washed with
PBS, scraped and resuspended in 3 ml labeling media
lacking methionine (Millipore Corp., Billerica MA). Cells
were then incubated for 15 minutes at 37°C to deplete the
endogenous methionine pool. After starvation cells were
pelleted again, resuspended in 400 μl of labeling medium,
and 150 μCi of [35S]-methionine was added to each sam-
ple. Cells were labeled for 90 minutes at 37°C. Then, cells
were pelleted (20 sec, 10,000 × g). The virus-containing
supernatant was removed and filtered through 0.45 μm
cellulose acetate spin filters (Corning Costar Corp., Cam-
bridge MA). Virions were lysed in 0.1% Triton-X100, 0.1%
bovine serum albumin (BSA) in PBS. Cells were lysed in
200 μl of Triton lysis buffer (50 mM Tris pH 7.5, 150 mM
NaCl, 0.5% Triton-X100) and incubated on ice for 5 min-
utes. After lysis, the cells were pelleted at 13,000 × g for 2
minutes to remove insoluble material. The supernatants
and the virus lysates were incubated on a rotating wheel
for 1 hr at 4°C with protein A-Sepharose coupled with an
HIV-positive patient serum. Beads were washed twice with
wash buffer (50 mM Tris pH 7.4, 300 mM NaCl, 0.1% Tri-
ton X-100). Bound proteins were eluted by heating in
sample buffer for 10 min at 95°C, separated by SDS-
PAGE, and visualized by fluorography.
Concanavalin A (ConA) and datura stramonium lectin (DS 
lectin) binding assays
For glycoprotein analysis of BST-2, cell lysates were pre-
pared as follows: Cells were washed once with PBS and
lysed in 300 μl of lysis buffer (50 mM Tris pH 8.0, 100
mM NaCl, 5 mM ethylenediaminetetraacetic acid, 0.5%
CHAPS) and 40 μl of DOC (2% deoxycholate in lysis
buffer). The cell extracts were clarified at 13,000 × g for 2
min and the supernatant was incubated on a rotating
wheel for 1-3 h at 4°C with ConA or DS lectin resin (Vec-
tor Laboratories, Burlingame CA) in 0.1% BSA-PBS. Com-
plexes were washed three times with 50 mM Tris, 300 mM
NaCl, and 0.1% Triton X100, pH 7.4. Bound proteins
were eluted from beads by heating in sample buffer for 5
- 10 min at 95°C and analyzed by immunoblotting.
Glycoprotein analysis
All digestions were performed directly on BST-2 bound to
either ConA or DS lectin resin. Control reactions con-
ducted in parallel did not contain enzyme. For endogly-
cosidase H (Endo H) and Peptide: N-Glycosidase F
analysis (PNGase) beads were washed with denaturing
buffer (New England BioLabs, Ipswich MA), then resus-
pended in denaturing buffer and boiled at 95°C for 10
min. The supplied reaction buffer was added along with
0.1% NP-40 according to the manufacturer's suggestion.
An excess of enzyme, 2500 units of Endo H (New England
BioLabs, Ipswich MA) or PNGase (New England BioLabs,
Ipswich MA), was added and samples were digested at
37°C for 3 h. Bound proteins were eluted from beads by
heating in an equal volume of sample buffer for 10 min at
95°C and analyzed by immunoblotting. For endo-β-
galactosidase (Endo B) analysis, beads were first washed
with 50 mM sodium acetate (pH 5.8), then resuspended
in the same buffer supplemented with BSA to 0.1%. 5 mU
of Endo B (Associates of Cape Cod, East Falmouth MA)
was added and digested at 37°C for 16 h along with a con-
trol lacking the enzyme.
FACS analysis
Cells were washed twice with ice-cold 20 mM EDTA-PBS,
followed by 2 washes in ice-cold 1% BSA-PBS. Cells were
treated for 10 min with 50 μg of mouse IgG (Millipore,
Temecula CA) to block non-specific binding sites. Cells
were incubated with primary antibody (α-BST-2) for 30
min at room temperature. Cells were then washed twice
with ice-cold 1% BSA-PBS followed by addition of allo-
phycocyanin (APC)-conjugated anti rabbit IgG secondary
antibody (Jackson Immuno Research Lab Inc., West Grove
PA) in 1% BSA-PBS. Incubation was for 30 min at room
temperature in the dark. Cells were then washed twice
with ice-cold 1% BSA-PBS and fixed with 1% paraformal-
dehyde in PBS. Finally, cells were analyzed on a FACS Cal-
ibur (BD Biosciences Immunocytometry Systems,
Mountain View CA). Data analysis was performed usingRetrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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Flow Jo (Tree Star, San Carlos CA). For gating of trans-
fected cells, pEGFP-N1 (Clontech, Mountain View CA)
was cotransfected.
Results
Endogenous and exogenously expressed BST-2 have 
distinct glycosylation profiles
The biochemical characterization of BST-2 necessitates
exogenous expression of the protein. For that purpose, the
BST-2 gene was PCR-amplified from HeLa cell mRNA and
cloned under the control of the cytomegalovirus immedi-
ate-early promoter as described in Methods. Ectopic
expression of BST-2 from pcDNA-BST-2 was analyzed by
immunoblot analysis of transiently transfected 293T cells
using a BST-2-specific antibody (Fig. 2A, lane 3). HeLa
cells expressing endogenous BST-2 (Fig. 2A, lane 1) and
mock-transfected 293T cells (Fig. 2A, lane 2) were ana-
lyzed in parallel. Endogenous BST-2 in HeLa cells
appeared as a smear of multiple bands with an apparent
Mr of 30-40 kDa, presumably due to N-linked glycosyla-
tion. Consistent with a previous report [24], untransfected
293T cells did not reveal BST-2 expression (Fig. 2A, lane
2). Of note, the bulk of transiently expressed BST-2 in
293T cells exhibited faster mobility in the gel than the
endogenous protein and had an apparent Mr of 28-29
kDa (Fig. 2A, lane 3, arrow). Only a minor fraction of the
exogenously expressed BST-2 protein exhibited an electro-
phoretic mobility comparable to that of the endogenous
protein in HeLa cells. The appearance of faster migrating
forms of exogenously expressed BST-2 is not cell type-spe-
cific and was observed in transiently transfected HeLa cells
as well (data not shown). Titrating transfected BST-2 DNA
to the limit of detection in 293T cells did not prevent the
appearance of the faster migrating forms of BST-2 (data
not shown). Thus, the appearance of faster migrating
forms of BST-2 in transiently transfected 293T cells are
presumably a result of transient expression rather than
protein overexpression per se.
Exogenously expressed BST-2 contains high-mannose as 
well as complex carbohydrate modifications
It has been previously reported that rodent BST-2 is glyco-
sylated, however the type of glycosylation has not been
examined [29,31] Smeared protein patterns similar to
BST-2 were previously observed for proteins with complex
carbohydrate modifications [44] and it was likely that the
30-40 kDa and 28-29 kDa forms of BST-2 detected in
transfected 293T cells above represented various carbohy-
drate modifications. We therefore performed an endogly-
cosidase analysis of transiently expressed BST-2.
Enzymatic reactions were performed on BST-2 that was
previously enriched by adsorption to either Concanavalin
A (ConA) or datura stramonium lectin (DS lectin) resin.
ConA recognizes α-linked high-mannose oligosaccha-
rides, which are intermediates in N-linked glycosylation
and are typically found on proteins that have not yet
exited the endoplasmic reticulum (ER); DS lectin on the
other hand binds β1-4 linked N-acetylglucosamine or N-
acetyllactosamine repeats, which are characteristic of fully
processed oligosaccharides and produce the smear pattern
on protein gels noted above [44]. The latter modifications
are typically found on glycoproteins that have exited the
ER (for review see [45]). Peptide:N-Glycosidase F
(PNGase) cleaves glycoproteins between the innermost
GlcNAc and asparagine residues of all oligosaccharides
from N-linked glycoproteins [46]. Therefore all N-linked
oligosaccharides will be sensitive to PNGase treatment.
Endo-β-N-acetylglucosaminidase H (EndoH), on the
other hand, is more selective than PNGase and cleaves the
chitobiose core of high-mannose from N-linked glycopro-
teins [46]. Because of that, ER associated proteins are gen-
erally sensitive to EndoH treatment. Proteins exiting the
ER to the Golgi typically undergo additional sugar modi-
fications and, as a result, become EndoH resistant. A third
type of endoglycosidase, endo-β-galactosidase (EndoB),
cleaves glycoproteins after β-galactosidic linkages [47]
typically observed on glycoproteins that have exited the
ER. Accordingly, glycoproteins residing in the ER are gen-
erally EndoB resistant.
As expected, PNGase treatment removed all oligosaccha-
rides (Fig. 2B &2C, lane 3) resulting in deglycosylated pro-
teins with a Mr of 17-19 kDa and appeared as a doublet.
The reason why deglycosylated BST-2 runs as a doublet is
not clear but could be due to other modifications such as
phosphorylation or the presence and absence of the GPI
anchor. PNGase-treated BST-2 samples adsorbed to DS
lectin columns revealed an additional protein doublet of
38-40 kDa (Fig. 2B, lane 3). The precise nature of this pro-
tein species is unclear but its mobility in the gel is consist-
ent with that predicted for a dimer form of BST-2. BST-2
enriched by DS lectin columns was largely resistant to
EndoH treatment (Fig. 2B, compare lanes 1 & 2). EndoH
resistance indicated that the 30-40 kDa population of
BST-2 contained complex sugar modifications and there-
fore has likely exited the ER. This was confirmed by their
sensitivity to EndoB treatment (Fig. 2B, lane 5). In con-
trast, the 28-29 kDa population of BST-2 enriched by
ConA was highly sensitive to EndoH (Fig. 2C, lane 2) but
was resistant to EndoB treatment (Fig. 2C, lane 5). These
results suggest that the 28-29 kDa protein population
observed in transfected 293T cells represents a high-man-
nose form of BST-2. Therefore, exogenously expressed
BST-2 consists of two populations: a 30-40 kDa form con-
taining complex sugar modifications (referred to as "post-
ER form" for the remainder of the text) and a predomi-
nant 28-29 kDa population containing high-mannose oli-
gosaccharide modifications (referred to as "high-mannose
form" in the following). HeLa cells expressing endog-
enous BST-2 were not entirely devoid of the high-man-Retrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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Figure 2 (see legend on next page)
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nose form of BST-2. However, the high-mannose form of
endogenous BST-2 was detectable in HeLa cells only on
over-exposed gels (compare lanes 1 in Figs. 2A &2D) but
could be enriched by adsorption of cell lysates to ConA
lectin (Fig. 2D, lane 3).
BST-2 is glycosylated at asparagine residues 65 and 92
The predicted amino acid sequence for BST-2 contains
two potential N-linked glycosylation sites at positions 65
and 92 of the 180 residue protein [30]. Previous studies
reporting on rodent BST-2 glycosylation did not clearly
address whether one or both of the two potential N-linked
glycosylation sites in the BST-2 ectodomain were modi-
fied [31]. To address this issue we mutated asparagine res-
idues 65 and 92 of human BST-2 to glutamine. Mutations
were introduced either individually into BST-2 to result in
mutants N1 (N65Q) and N2 (N92Q), respectively, or in
combination to result in mutant N1/N2 (N65,92Q).
Mutants were expressed in 293T cells and analyzed by
immunoblotting using a BST-2-specific antibody. As
shown in figure 3A, mutation of individual glycosylation
sites reduced the apparent Mr of the N1 as well as the N2
mutant relative to the wild type (wt) protein (Fig. 3A, top
panel; lanes 1-3). Mutation of both potential glycosyla-
tion sites in the double mutant (N1/N2) further reduced
the apparent Mr of the predominant 28-29 kDa species to
about 17-19 kDa (Fig. 3A, top panel; lane 4) closely
matching the predicted Mr of 19.7 kDa for non-glyco-
sylated BST-2. These results indicate that both predicted
glycosylation sites at BST-2 residues N65 and N92 are
modified.
The use of both glycosylation sites was further verified by
a pull-down experiment using ConA resin (Fig. 3A, mid-
dle panel) and DS lectin resin (lower panel). As can be
seen, wt BST-2 and the N1 and N2 single glycosylation
mutants interacted with ConA and DS lectin. As predicted,
the N1/N2 double mutant had no affinity to ConA or DS
lectin due to the lack of oligosaccharide modification of
this BST-2 mutant.
Glycosylation of BST-2 is not required for inhibition of 
virus release and sensitivity to Vpu
To assess the importance of BST-2 glycosylation for the
inhibition of virus release and for sensitivity to Vpu (i.e.
reduction of BST-2 steady state levels) we performed a set
of experiments, in which the release of metabolically
labeled viral Gag proteins was determined in the presence
of increasing amounts of wt BST-2 or the N1/N2 BST-2
double glycosylation mutant. For that purpose wt NL4-3
or NL4-3/Udel were transfected into 293T cells either
alone or in combination with wt BST-2 or BST-2 N1/N2 at
virus:BST-2 ratios of 500:1 to 50:1. Prior to labelling, a
portion of the transfected cells was removed to allow
simultaneous analysis of intracellular BST-2 expression by
immunoblotting. As shown in figure 3B transfection of
increasing amounts of BST-2 DNA resulted in the dose-
dependent increase in BST-2 expression (lanes 2-4 & 6-8).
BST-2 wt and N1/N2 were expressed at comparable levels
but exhibited different mobilities in the gel. Like the
PNGase-treated samples in figure 2B, a sub-population of
non-glycosylated N1/N2 protein exhibited mobility in the
gel predicted for a BST-2 dimer (Fig. 2B, arrow). As
reported previously [37], Vpu has the ability to reduce the
expression of BST-2 [37-40]. Expression of Vpu in the
samples was verified by immunoblotting (Fig. 3B, Vpu)
and equal sample loading was verified by reprobing the
blot with a tubulin-specific antibody (Fig. 3B, tub). Of
note, levels of wt BST-2 as well as the N1/N2 mutant were
lower in samples cotransfected with wt NL4-3 than in the
corresponding NL4-3/Udel samples (compare lanes 2-4 &
6-8). This suggests that BST-2 N1/N2 expression, like wt
BST-2, is sensitive to Vpu. Both the high mannose and
post-ER form of BST-2 were sensitive to Vpu.
To assess the importance of glycosylation on BST-2's abil-
ity to inhibit virus release, transfected cells were labeled
for 90 min with [35S]-methionine and cell lysates and cell-
free virus-containing supernatants were immunoprecipi-
tated with an HIV-positive patient serum as described in
Methods. Samples were separated by SDS-PAGE and
immunoprecipitated proteins were visualized by fluorog-
raphy (Fig. 4A &4B, left panels). Virus release was quanti-
Comparison of endogenous BST-2 in HeLa cells to BST-2 expressed in transiently transfected 293T cells Figure 2 (see previous page)
Comparison of endogenous BST-2 in HeLa cells to BST-2 expressed in transiently transfected 293T cells. (A) 
293T cells were transfected with wt BST-2 (lane 3). A mock transfected culture from HeLa (lane 1) and 293T cells (lane 2) was 
analyzed in parallel. Whole cell lysates were processed for immunoblotting as described in Methods. The arrow identifies a 
BST-2 species in transfected 293T cells not seen in HeLa cells. (B & C) Endoglycosidase analysis of transiently expressed BST-
2. 293T cells were transfected with pcDNA-BST-2. BST-2 was enriched by adsorption to either datura stramonium lectin resin 
(DS lectin) (B) or Concanavalin A resin (ConA) (C) as described in Methods. DS lectin or ConA bound proteins were either 
left untreated (lanes 1 & 4) or treated with endoglycosidase H (EndoH) (lanes 2), Peptide: N-Glycosidase F (PNGase) (lanes 3), 
or endo-β-galactosidase (EndoB) (lanes 5) as described in Methods. Proteins were visualized by immunoblot analysis using a 
BST-2 specific antibody. (D) HeLa extracts were adsorbed to DS lectin (lane 2) and ConA resin (lane 3) as described for pan-
els B & C. Total input lysate is shown in lane 1. A high mannose form of endogenous BST-2 was enriched on the ConA resin.Retrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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fied by phosphoimage analysis (Fig. 4A &4B, right
panels). The amount of viral protein in the cell-free super-
natant was calculated as percentage of the total intra- and
extra-cellular protein and was plotted as a function of BST-
2 concentration on a semi-log plot. In the absence of BST-
2 between 10-20% of total Gag protein was released
within the 90 minute window of this experiment. As
expected, wt BST-2 significantly reduced the release of vpu-
deficient HIV-1 virions into the culture supernatants in a
dose-dependent manner while it had no significant effect
on the release of wt virus (Fig. 4A). Interestingly, the N1/
N2 BST-2 glycosylation mutant inhibited release of Vpu-
deficient virus to a similar extent as wt BST-2 and did not
inhibit release of wt NL4-3 (Fig. 4B). We therefore con-
clude that glycosylation of BST-2 is not critical for the
inhibition of virus release and does not affect sensitivity of
BST-2 to Vpu.
Any one of three cysteines in the BST-2 ectodomain can 
mediate BST-2 dimerization
In addition to glycosylation, other predicted modifica-
tions in BST-2 arise from the ability to homo-dimerize
[29]. We verified this property of BST-2 by analyzing
endogenous BST-2 from HeLa cells under reducing and
non-reducing conditions. HeLa extracts were prepared as
described in the Methods section and separated by SDS-
PAGE. To prevent inadvertent reduction of the non-
reduced sample by the mercapto-ethanol present in the
reduced sample, samples were separated by two empty
lanes in the gel. As can be seen in figure 5A, BST-2, when
Immunoblot analysis of BST-2 glycosylation mutants Figure 3
Immunoblot analysis of BST-2 glycosylation mutants. (A) 293T cells were transfected with wt BST-2, single glycosyla-
tion site mutants N1 & N2, or the double glycosylation site mutant N1/N2. BST-2 specific proteins were identified by immuno-
blotting using a BST-2-specific polyclonal antibody (top panel). Aliquots of the same samples were adsorbed to either ConA 
(middle panel) or DS lectin (lower panel) as described in Methods. Eluates were analyzed by immunoblotting using a BST-2-
specific polyclonal antibody. (B) 293T cells were transfected with 5 μg each of NL4-3 wt (lanes 1-4) or NL4-3/Udel (lanes 5-8) 
either in the absence of BST-2 (lanes 1 & 5) or in the presence of 0.01 μg (lanes 2 & 6), 0.03 μg (lanes 3 & 7), or 0.1 μg (lanes 
4 & 8) BST-2 DNA. Cells were harvested 20 h post transfection. A fraction of the cells was used for immunoblot analysis; the 
other part was used for metabolic labelling (Fig. 4). Whole cell lysates were prepared and used for immunoblot analysis using a 
BST-2-specific polyclonal antibody (top two panels). The blots were then sequentially reprobed with antibodies to Vpu (third 
panel) or tubulin (lower panel). Representative samples shown in the lower panels were from the N1/N2 blot. Proteins are 
identified on the right. The arrow points to a form of BST-2 N1/N2 whose migration in the gel is consistent with a dimer.
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prepared under non-reducing conditions (- β-ME), quan-
titatively shifted into a slower migrating form with an Mr
of ~65-70 kDa consistent with the predicted position of a
BST-2 dimer.
BST-2 contains three cysteine residues in its extracellular
domain that could be involved in the formation of
cysteine-linked dimers (Fig. 1). We mutated the cysteines
at positions 53, 63, and 91 individually or in combina-
tions of two to alanine to obtain mutants C53A, C63A,
C91A, C12, C13, and C23, respectively. In addition, we
created a mutant, C3A, in which all three of these
cysteines were changed to alanine. The mutants are sche-
matically depicted in figure 5B. The ability of these
mutants to form cysteine-linked homo-dimers was tested
in transiently transfected 293T cells. All cysteine mutants
produced a dominant 28-29 kDa high-mannose form of
BST-2 (Fig. 5C/D, HM) in addition to the 30-40 kDa post-
ER form carrying complex sugar modifications. The com-
bined mutation of all three extracellular cysteines in C3A
affected the mobility of the post-ER form of BST-2 result-
ing in a more compressed, less smeared pattern (Fig. 5C
lane 2; 5D, lane 5). The reason for this is unclear but could
be indicative of altered oligosaccharide processing of
monomeric BST-2. Protein analysis under non-reducing
conditions demonstrated that mutation of individual
cysteines had no impact on the ability of BST-2 to homo-
dimerize (Fig. 5C, lanes 8-10). Similarly, mutation of two
of the three cysteine residues in any combination did not
affect BST-2 dimerization (Fig. 5D, lanes 7-9). Equal
Glycosylation of BST-2 is not required for inhibition of virus release and for sensitivity to Vpu Figure 4
Glycosylation of BST-2 is not required for inhibition of virus release and for sensitivity to Vpu. (A) Analysis of wt 
BST-2. (B) Analysis of BST-2 N1/N2. (A & B) Cells were metabolically labeled for 90 min with [35S]-methionine as described 
in Methods and cell lysates and cell-free supernatants were subjected to immunoprecipitation by an HIV-positive patient 
serum. Immunoprecipitates were subjected to SDS-PAGE and proteins were visualized by fluorography (left panels). Virus 
release was quantified by phosphoimage analysis using a Fujifilm FLA7000. Virus release was calculated independently for each 
sample by determining the percentage of cell-free CA protein relative to the total intra- and extra-cellular Gag protein. Solid 
circles represent wt NL4-3. Open circles represent NL4-3/Udel. Data are presented as a function of BST-2 concentration on a 
semi-log plot.
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amounts of DNA were transfected in all samples. Never-
theless, relative protein levels in the samples varied, per-
haps due to differences in protein stability or antibody
recognition. As predicted, mutation of all three cysteines
abolished BST-2 dimerization (Fig. 5C, lane 7; 5D, lane
10). These results suggest that any one of three cysteines
in the BST-2 extracellular domain can mediate BST-2
dimerization. Finally, it is interesting that the relative
prevalence of the high-mannose (HM) form of BST-2 did
not change under non-reducing conditions, while the
post-ER form of BST-2 is no longer present at the same
size under non-reducing conditions suggesting that only
the post-ER form of BST-2 can efficiently homo-dimerize
while the high mannose form remains largely, if not
exclusively, in monomeric form.
BST-2 dimerization is important for inhibition of virus 
release
The importance of cysteine-linked dimerization of BST-2
for inhibition of virus release was assessed by metabolic
labeling as described for the glycosylation mutants (Fig.
4) by coexpressing increasing amounts of BST-2 mutants
with constant amounts of wt NL4-3 or NL4-3/Udel. At the
same time, effects of Vpu on steady-state expression of
BST-2 cysteine mutants were assessed by immunoblotting
of cell lysates. Because double-cysteine mutants retained
the ability to form cysteine linked dimers, individual
cysteine mutants were ignored here and only double- and
triple-cysteine mutants were tested for the ability of Vpu
to decrease Bst-2 expression or to inhibit virus release. As
observed for the glycosylation mutants, intracellular
expression of the double- and triple-cysteine mutants was
sensitive to Vpu to varying degrees (Fig. 6). In particular
the C13 and C3A mutants were highly sensitive to Vpu
similar to wt BST-2 while expression of the C12 and C23
mutants appeared to be less affected by the presence of
Vpu. The reason for the differential sensitivity of these
mutants to Vpu is unclear. Metabolic labelling followed
by immunoprecipitation with an HIV-positive patient
serum revealed that all of the double-cysteine mutants
inhibited the release of Vpu-defective virus in a dose-
dependent manner (Fig. 7; top three panels). In contrast,
mutation of all three cysteines in the BST-2 ectodomain
abolished its ability to inhibit virus release (Fig. 7, bottom
panel). Inhibition of virus release by the cysteine mutants
of BST-2 was specific since none of the mutants inhibited
the release of wt virus. We therefore conclude that
cysteine-linked homo-dimerization of BST-2 is important
for the inhibition of HIV-1 virus release. These results also
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BST-2 forms cysteine-linked dimers Figure 5
BST-2 forms cysteine-linked dimers. (A) HeLa cells 
were lysed in reducing (+β-ME) or non-reducing (-β-ME) 
sample buffer as described in Methods. Lysates were sepa-
rated by SDS-PAGE and subjected to immunoblot analysis 
using a BST-2-specific polyclonal antibody. (B) Schematic 
representation of mutants analyzed in this experiment. In all 
cases, cysteine residues were mutated to alanine by site-
directed mutagenesis. Remaining cysteine residues are shown 
for each mutant. (C) 293T cells were transfected with wt 
BST-2 (lanes 1 & 6), the triple cysteine mutant C3A (lanes 2 
& 7), or individual cysteine mutants (lanes 3-5 & 8-10). Cells 
were harvested 24 h post transfection, washed in PBS, and 
split into two equal samples. One set of samples was mixed 
with an equal volume of reducing sample buffer (lanes 1-5); 
the second set was mixed with sample buffer lacking β-ME 
(lanes 6-10). Cell lysates were separated by SDS-PAGE and 
subjected to immunoblotting using a BST-2 specific antibody. 
(D) 293T cells were transfected with wt BST-2 (lanes 1 & 6), 
the triple cysteine mutant C3A (lanes 5 & 10), or double-
cysteine mutants (lanes 2-4 & 7-9). Samples were analyzed 
under reducing and non-reducing conditions as in panel C. 
(HM) marks the position of the high-mannose forms of BST-2 
in the gels.Retrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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indicate that BST-2 dimerization is not dependent on one
specific cysteine residue but can be mediated by any one
of the three cysteine residues present in the protein's ecto-
domain. Because of the presence of three dimerization-
competent cysteine residues, it is conceivable that BST-2
forms cysteine-linked homo-oligomeric structures. Stud-
ies are ongoing to investigate this possibility.
Lack of cysteine-linked dimerization and carbohydrate 
modification of BST-2 does not preclude cell surface 
expression and surface downregulation by Vpu
We and others have previously reported that Vpu does
have the ability to down-regulate BST-2 from the cell sur-
face [23,26,33,37,37-40]. The inability of the BST-2 C3A
mutant to inhibit virus release could be caused by cellular
mislocalization resulting in lack of surface expression. To
test this possibility we analyzed cell-surface expression
and Vpu-dependent cell-surface down modulation in
transiently transfected 293T cells. Vpu was expressed from
a codon-optimized vector [42] together with wt BST-2 or
the C3A or N1/N2 mutants (Fig. 8). A GFP expression vec-
tor was cotransfected to allow gating of transfected cells.
This experimental setup was previously shown to be a reli-
able assay system for studying Vpu-induced BST-2 cell sur-
face down modulation [23,37] FACS analysis revealed
that both the cysteine-deficient BST-2 (C3A) and the non-
glycosylated BST-2 (N1/N2) were expressed at the surface
Dimerization of BST-2 is not a prerequisite for sensitivity to  Vpu Figure 6
Dimerization of BST-2 is not a prerequisite for sensi-
tivity to Vpu. 293T cells were transfected with 5 μg of wt 
pNL4-3 (lanes 1-4) or pNL4-3/Udel (lanes 5-8) in the 
absence of BST-2 (lanes 1 & 5) or together with 0.01 (lanes 2 
& 6), 0.03 (lanes 3 & 7), and 0.1 μg (lanes 4 & 8) of vectors 
encoding cysteine mutants of BST-2 containing only one 
remaining cysteine (C12, C23, C13) or no cysteine at all 
(C3A). Twenty-four hours later, cell lysates were prepared 
from a fraction of the cells as described in the Methods and 
subjected to immunoblot analysis using a BST-2-specific anti-
body.
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Dimerization of BST-2 is important for inhibition of virus  release Figure 7
Dimerization of BST-2 is important for inhibition of 
virus release. Transfected 293T cells from figure 6 were 
metabolically labeled for 90 minutes and analyzed as 
described for figure 4. Proteins were identified by fluorogra-
phy (left panels). Quantification of virus release was per-
formed as described for figure 4 and is shown on the right.
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Monomeric BST-2 and non-glycosylated BST-2 are expressed at the cell surface and are sensitive to Vpu-induced down modu- lation Figure 8
Monomeric BST-2 and non-glycosylated BST-2 are expressed at the cell surface and are sensitive to Vpu-
induced down modulation. 293T cells were transfected with 0.1 μg each of wt BST-2, BST-2 C3A, or BST-2 N1/N2 
together with 1 μg each of pEGFP-N1 in the presence or absence of 1 μg pcDNA-Vphu. All samples were adjusted to 5 μg 
total DNA with empty vector DNA. Cells were harvested 24 h after transfection and stained with an antibody to BST-2. As a 
control, 293T cells were transfected with pEGFP-N1 and empty vector in the absence of BST-2 and stained with BST-2 anti-
body (Ctrl). Samples were subjected to FACS analysis as described in Methods and gated for GFP-positive cells. The red line 
represents the control of GFP+/BST-2- cells. Blue lines represent BST-2 staining in the absence of Vpu and green lines indicate 
BST-2 staining in the presence of Vpu. Numbers in the boxed legends represent mean fluorescence intensities for each sample.
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of transfected 293T cells (Fig. 8; blue lines) and were
down-modulated by Vpu (Fig. 8; green lines). The mean
fluorescence intensity of cell-surface C3A was higher in
this experiment than that of wt BST-2 (Fig. 8, numbers in
insets represent mean fluorescence intensity), perhaps
due to increased protein stability or stronger affinity to the
BST-2 antibody (or both). This was not further investi-
gated as it does not affect the overall conclusion from this
experiment, which is that neither N-linked glycosylation
nor BST-2 dimerization are required for cell-surface
expression and down-modulation by Vpu. These results
further support the notion that inhibition of virus release
and sensitivity to Vpu are independent properties of BST-
2.
Discussion
The identification of BST-2/tetherin as a Vpu-sensitive
host factor has spurred new interest in the role of Vpu dur-
ing HIV-1 particle release. Neil et al proposed a tethering
mechanism where BST-2 acts in the manner of a bifunc-
tional crosslinker to physically link otherwise fully
detached virions to the cell surface or to each other [24].
Such a mechanism is very attractive but would be difficult
to explain without virus-association of BST-2. Experimen-
tal proof for the tethering model remains to be estab-
lished. Our own analyses have thus far failed to identify
mature forms of BST-2 in virion preparations recovered
from the surface of transfected HeLa cells by physical
shearing [37]. It is of course possible that virus-associated
amounts of mature BST-2 are simply below the limit of
detection even though we were able to detect low levels of
non-specifically secreted mature BST-2 [37]. In this regard
it is interesting to note that high-mannose forms of BST-2,
which are heavily overexpressed relative to mature BST-2
in transiently transfected 293T cells (e.g. figure 2A), were
indeed observed in cell-free virion preparations (data not
shown). However, the significance of this observation
remains unclear since these BST-2 forms are not readily
seen under physiological conditions. High mannose
modifications are typical of ER-resident glycoproteins.
However, there are a few examples, in which high man-
nose-modified glycoproteins were identified at the cell
surface [48,49] Therefore, more work will be required to
fully understand how BST-2 traffics to the cell surface and
how it inhibits the release of HIV-1 virions. It also remains
to be shown how Vpu enables the virus to bypass the
inhibitory effect of BST-2. We confirmed that Vpu can
cause surface downmodulation and reduction of intracel-
lular levels of BST-2. While it is not entirely clear whether
these effects of Vpu are prerequisites to efficient virus
release [37], they provide useful analytical tools and were
used here to test the sensitivity of BST-2 mutants to Vpu in
vitro.
To get a better understanding of BST-2 and its role in HIV-
1 virus release, we performed a biochemical characteriza-
tion of BST-2 and studied how the biochemical properties
relate to BST-2 function. BST-2 is a transmembrane glyco-
protein that forms cysteine-linked homo-dimers and is
expressed at the cell surface. All of our experiments were
done with authentic untagged protein; yet, transiently
expressed BST-2 exhibited dramatically different mobility
on SDS PAGE than endogenous protein expressed in HeLa
cells. We found that a large portion of transiently
expressed BST-2 remained in a high-mannose form typical
of ER associated proteins. The high-mannose form of BST-
2 is not typically seen for endogenously expressed BST-2
in HeLa cells but can be induced by treatment with brefel-
din A (BFA), a drug known to block export of membrane
proteins from the ER (data not shown) and can be
enriched by adsorbing lysates of untreated HeLa cells to
ConA lectin (Fig. 2D). Reducing amounts of transfected
DNA did not prevent accumulation of the high-mannose
form in transient expression studies (e.g. Figs. 3B &6)
indicating that it represents a relatively dose-independent
phenomenon. Also, the effect was cell type-independent
and seen in 293T and transiently transfected HeLa cells.
Importantly, the relative abundance of high mannose
BST-2 in transiently transfected 293T cells relative to
endogenous BST-2 in HeLa cells did not abolish BST-2
function, as transiently expressed protein was capable of
specifically and efficiently inhibiting virus release in the
absence but not in the presence of Vpu. It is currently
unclear if the accumulation of the high-mannose form of
transiently expressed BST-2 is caused by a bottleneck effect
delaying or preventing exit of BST-2 from the ER or
whether BST-2 can exit the ER and bypass the complex
sugar modification machinery of the Golgi altogether. On
the other hand, we were able to detect high-mannose
modified BST-2 in cell free virus preparations (data not
shown), which could suggest that some of the protein is
capable of trafficking to the cell surface without acquiring
complex sugar modifications in the ER. While there is
precedent in the literature for such a scenario [48,49], it is
equally possible that extracellular BST-2 in such experi-
ments was inadvertently released from a small number of
cells that might have been destroyed during sample prep-
aration. While we have referred to the different forms of
BST-2 as "high-mannose" and "post-ER", we cannot
unambiguously conclude that the high-mannose form of
BST-2 represents an ER-resident form since we do not
have reagents to discriminate the various forms of BST-2
by FACS or IFA. However, our observation of the func-
tional importance of cysteine-linked dimers (discussed
below), combined with the observation that the high-
mannose form of BST-2 does not appear to dimerize,
could imply that the high-mannose form of BST-2 is func-
tionally inert. The biological role of BST-2 carrying high-
mannose carbohydrate modifications will require addi-Retrovirology 2009, 6:80 http://www.retrovirology.com/content/6/1/80
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tional investigation; however, we can already conclude
that glycosylation per se is neither required for protein exit
from the ER nor for cell surface presentation. This conclu-
sion is based on our observation that the glycosylation-
deficient N1/N2 mutant was not only expressed at the cell
surface but inhibited the release of Vpu-deficient HIV-1
virions with similar efficiency as wt BST-2 and was sensi-
tive to downregulation by Vpu (Figs. 4 &8).
Interestingly, while glycosylation of BST-2 appears to be
functionally insignificant, formation of cysteine-linked
dimers was important for BST-2's inhibitory effect on
virus release. BST-2 encodes three cysteines in its ectodo-
main. Our results suggest that formation of cysteine-
linked dimers is not mediated by any one specific cysteine
residue in the ectodomain since mutation of each cysteine
individually or in combination of two did not affect pro-
tein dimerization. The fact that none of these mutations
affected BST-2 function supports the notion that the loss
of activity seen for the triple cysteine mutant is due to the
lack of protein dimerization rather than caused by a
change in the amino acid sequence. The fact that the BST-
2 triple cysteine mutant C3A was expressed at the cell sur-
face and that cell surface expression was sensitive to Vpu
(Fig. 8) further suggests that the lack of dimerization does
not critically impair intracellular trafficking of the mutant
protein. BST-2 dimerization could favor a tethering model
since protein dimerization might have a stabilizing effect
and strengthen the link between viral and cellular mem-
branes. Studies on Ebola virus release found that treat-
ment of cells with up to 500 mM DTT did not reverse the
inhibitory effect of BST-2 [50]. While this could suggest
that BST-2 dimers are not functionally important, it is
equally possible that these conditions were not sufficient
to reduce the BST-2 dimers. In some of our experiments,
BST-2 dimers were seen even after boiling of the samples
in reducing buffer (e.g. Fig. 2B, lane 3; Fig. 3B). Thus, BST-
2 dimers appear to be quite stable and the effects of reduc-
ing agents on the dimer structure of BST-2 and on the
shedding of vpu-deficient particles from HeLa cells will be
interesting to investigate in future studies.
Finally, assuming BST-2 inhibits virus release from the cell
surface we would predict that BFA treatment, which can
trap BST-2 in the ER, will render virus release from HeLa
cells Vpu-independent. However, in a previous study we
found that virus release in BFA-treated HeLa cells was
reduced to the level of untreated Vpu-negative cells irre-
spective of the presence or absence of Vpu [51]. Thus, BFA
treatment did not render virus release from HeLa cells
Vpu-independent but, quite to the contrary, Vpu insensi-
tive. It is not clear at this time whether BFA treatment pre-
vents Vpu from reaching its proper intracellular location
required for targeting BST-2 or whether a 4 hour BFA-
treatment cannot sufficiently reduce surface expression of
BST-2. Experiments are ongoing to solve this conundrum.
Our experiments do not address the question where in the
cell BST-2 functions to inhibit virus release, however the
high-mannose form of BST-2 appeared to be less sensitive
to Vpu than the post-ER form (Figures 3 &6). Dube et al
recently reported that regulation of virus release correlates
with localization of Vpu in the trans-Golgi network [52].
Our own previous experiments have identified Vpu at the
cell surface of transfected HeLa cells although cell surface
levels of Vpu are likely to be low [53]. Thus, Vpu could act
at the cell surface to displace BST-2 from the site of virus
budding or it could act from within the cell by affecting
BST-2 trafficking [38,52] Deciphering the mechanism of
Vpu function will be a major focus of our future work in
this area.
Conclusion
Our study provides first insights into the functional
importance of cysteine-linked dimers of BST-2 while at
the same time demonstrating the relative unimportance
of N-linked glycosylation for the inhibition of virus
release. Interestingly, the loss of activity of a BST-2 mutant
unable to form cysteine-linked dimers was not caused by
lack of cell surface expression. Also, the dimerization
mutant remained sensitive to Vpu, thus ruling out gross
mislocalization and misfolding of the protein. We there-
fore conclude that formation of cysteine-linked BST-2
dimers is a functional requirement for inhibition of virus
release. Finally, we observed that transient expression of
BST-2 leads to the production of a dominant high man-
nose form of BST-2 that is present but underrepresented in
the pool of endogenous protein. Although high mannose
modifications are typical for ER resident glycoproteins,
there are examples in the literature for cell-surface
expressed, high mannose modified glycoproteins. How-
ever, the overall difference in protein modification of
endogenous versus exogenous BST-2 could be indicative
of differences in their relative intracellular distribution.
This phenomenon needs to be taken into consideration in
particular for future analyses of BST-2 intracellular traf-
ficking.
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